Login / Signup

Low-molecular-weight heparin beyond 12 months in patients with cancer-associated thrombosis.

Sergio Lopez-RuzMaria Barca-HernandoSamira Marin-RomeroTeresa Elias-HernandezRemedios Otero-CandeleraLuis Jara Palomares
Published in: British journal of cancer (2022)
In patients with cancer-associated thrombosis under anticoagulant treatment with LMWH, the rate of clinically relevant bleeding and major bleeding were lower beyond 12 months.
Keyphrases
  • atrial fibrillation
  • pulmonary embolism
  • venous thromboembolism
  • growth factor
  • replacement therapy